Where does Sarepta Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	——	$235.24M+140%	-$581.63M+17.3%	-$703.49M-68.0%
Depreciation and amortization	$44.52M+18.0%	$37.72M-15.0%	$44.4M+6.1%	$41.86M+10.1%
Stock-based compensation	$123.4M-33.0%	$184.3M+1.0%	$182.51M-21.7%	$233.02M+105%
Change in accounts receivable	-$206.25M-202%	$201.66M+8.6%	$185.7M+190%	$63.98M+23.9%
Change in inventories	$319.57M-19.1%	$395.17M+168%	$147.71M+191%	$50.78M-39.4%
Change in accounts payable	——	——	——	——
Change in accrued liabilities	——	——	——	——
Change in other assets	——	——	-$1.81M-106%	$27.94M+127%
Other working capital changes	-$7.06M—	——	——	——
Change in deferred revenue	$72.05M—	——	-$86.83M+2.7%	-$89.24M0.0%
Net gains (losses) on investments	——	$0—	——	-$2.58M—
Net cash from operating activities	——	——	-$500.99M-54.0%	-$325.35M+26.6%
Capital expenditures	$101.97M-25.5%	$136.96M+80.0%	$76.11M+147%	$30.82M-19.9%
Purchases of investments	——	$1.1B-46.2%	$2.04B+5.6%	$1.94B—
Proceeds from maturities/sales of investments	$174.1M—	$0—	$0-100%	$923.22M+98.1%
Purchases of intangible assets	$7.88M—	——	$11.24M—	——
Net cash from investing activities	——	——	-$165.8M—	——
Proceeds from issuance of debt	——	——	——	$0—
Repayments of debt	——	——	——	$550M—
Proceeds from issuance of common stock	$20M—	$0—	$0—	$0—
Net cash from financing activities	-$168.34M-235%	$124.81M-0.2%	$125M-46.2%	$232.51M-58.6%
Net increase (decrease) in cash	——	$674.58M+225%	-$541.79M—	——
Interest paid	$14.91M-5.9%	$15.86M-0.4%	$15.92M-64.2%	$44.42M-20.6%
Income taxes paid	$37.63M+66.6%	$22.59M+49.8%	$15.08M—	——
Accretion Of Investment Discount Net	-$5.29M+86.9%	-$40.28M+12.8%	-$46.18M-334%	-$10.65M-10,342%
Gain (Loss) on Investments	——	——	——	——
Accrued expenses and other liabilities	——	——	——	——
Deferred revenue	$72.05M—	——	-$86.83M+2.7%	-$89.24M0.0%
Increase Decrease In Manufacturing Related Deposits And Prepaids	——	——	$12.52M+129%	-$42.56M—
Increase (Decrease) in Other Operating Assets	——	——	-$1.81M-106%	$27.94M+127%
Non Cash Inventory Write Downs For Excess And Obsolescence	$165.26M—	$0—	$0—	——
Noncash Interest Expense	——	——	——	$7.55M-0.4%
Other Noncash Income (Expense)	-$7.06M—	——	——	——
Reduction In The Carrying Amounts Of The Right Of Use Assets	$13.95M-13.7%	$16.17M+11.5%	$14.5M+13.8%	$12.74M+12.5%
Acquisition Of Strategic Investments	——	$0+100%	-$4M-300%	-$1M+44.4%
Payments to Acquire Intangible Assets	$7.88M—	——	$11.24M—	——
Proceeds From Sale And Maturity Of Available For Sale Securities	$295.87M-85.2%	$2B+7.2%	$1.87B+102%	$923.22M+98.1%
Payment On Maturity Of Notes	$0-100%	$68K—	$0—	$0—
Payments Related To Obtaining Revolving Credit Facility	$4.17M—	$0—	$0—	——
Settlement Of Capped Call Share Options For2024Notes	$0-100%	$45.35M-43.8%	$80.65M+206%	$26.32M—
Contingent Consideration Liabilities Derecognized	$47.4M—	$0—	$0—	——
Incremental Option Value Associated With The December2025Exchange	$21.08M—	$0—	$0—	——
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1	——	$42.74M—	——	$7.01M—
Remeasurement Of Embedded Lease Liabilities	$12.27M—	$0—	$0—	——
Leased assets obtained in exchange for operating lease liabilities	——	$35.36M-55.9%	$80.2M+100%	$40.01M+203%
Income Taxes Paid, Net	$37.63M+66.6%	$22.59M+49.8%	$15.08M—	——
Free cash flow	——	——	-$577.1M-62.0%	-$356.17M+26.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Sarepta Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.